BUSINESSCNBC TOP
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biotech IPOs are gaining momentum while big pharmaceutical companies drive M&A activity to replenish drug pipelines before major patent expirations later this decade.
Mentioned
Related Signal
Adjacent reporting
- Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
- Which company could become the Chinese Pfizer? Here are analysts’ top picks
- AI companies are barreling toward huge Wall Street debuts. A look at the biggest players
- STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much more
- Which company could become the Chinese Pfizer? Here are analysts’ top picks